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http://dx.doi.org/10.1016/j.jacl.2016.04BACKGROUND: The discontinuation of statin medication is associated with an increased risk of car-
diovascular and cerebrovascular events and, among high-risk patients, all-cause mortality, but the rea-
sons for discontinuation among statin initiators in clinical practice are poorly understood.
OBJECTIVE: To examine factors predicting the early discontinuation of statin therapy.
METHODS: In this prospective cohort study, participants with baseline measurements before the
initiation of statin treatment were linked to national registers and followed for the discontinuation of
statins during the first year of treatment (no filled prescriptions after statin initiation within the subse-
quent 12 months).
RESULTS: Of all the 9285 statin initiators, 12% (n 5 1142) were discontinuers. Obesity, over-
weight, vascular comorbidities, and older age were independently associated with a reduced risk of
discontinuation [odds ratios (OR) 5 0.82 (95% confidence interval [CI], 0.69–0.99), 0.85 (95% CI,
0.73–0.98), 0.80 (95% CI, 0.68–0.93), and 0.82 (95% CI, 0.68–0.99), respectively]. In contrast,
high-patient cost-sharing was associated with an increased odds (OR 5 1.29; 95% CI, 1.03–1.62)
for discontinuation. The only significant difference between the sexes (P 5 .002) was observed among
the participants with risky alcohol use, which was associated with a decreased odds for discontinuation
among the men (OR 5 0.69; 95% CI, 0.49–0.98) and an increased odds among the women (OR 5
1.28; 95% CI, 1.02–1.62).
CONCLUSIONS: The discontinuation of statin therapy during the first year after initiation is com-
mon. Lowering out-of-pocket expenditures and focusing on low-risk patient groups and women with
risky alcohol use could help maintain the continuation of medication.
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What is already known about this subject?
Despite well-documented benefits of statins, discontinu-
ation of statin medication is common among primary
and secondary prevention patients.
What does this study add?
Several predictors of discontinuation are readily assess-
able and can provide information with which to identify
those with an increased risk of nonadherence.
How might this impact on clinical practice?
In clinical practice, many patients for whom statins are
prescribed discontinue the use of the drug within a
year, which is likely to reduce any benefit of medication
and increase the risk of cardiovascular events. Increased
efforts to motivate treatment adherence in risk groups
988 Journal of Clinical Lipidology, Vol 10, No 4, August 2016could reduce discontinuation and cardiovascular events.Introduction
Statins are one of the most widely studied and evidence-
based medications1 and are an essential component of car-
diovascular disease prevention. Statins are well tolerated,
safe, and inexpensive (when following the generic substitu-
tion). Despite these well-documented benefits, poor
adherence to statins and an extreme form of it, discontinua-
tion—that is, quitting statin medication use2—is common
among primary and secondary prevention patients.3–6 In
clinical trials, the discontinuation rates range from 4% to
11%,7–9 but in routine care, the rates are much higher; be-
tween 11% and 53%.2,3,10,11 According to studies using
electronic medical records, approximately 25% to 50% of
patients discontinue statin use within six months to
one year after initiating their use.4,5,12 The number of pa-
tients continuing therapy falls sharply in the first few months
of treatment, followed by a more gradual decline.4,13
Discontinuation is commonly attributed to statin-related
adverse events, but, because most patients who reinitiate
statin use can tolerate this medication long-term,2 many of
these events may have had other etiologies. Previous
studies on the determinants of discontinuation have re-
ported mixed results. Some found a greater tendency to dis-
continue statin treatment among the young (,50 years) or
old (.70 years),11,14–16 with high co-payment,2,3,17,18 for
primary prevention patients,3,5,15,19–21 and intensive dose
therapy.22 An increased risk of statin discontinuation has
also been found for smokers,20 and patients with dia-
betes20,23 despite the current guidelines recommending
statin medication for nearly all patients with type 2 dia-
betes.24 On the contrary, one study found diabetes to be
associated with the continuation of lipid-lowering drugs
(of which statins accounted for 69%).25 However, other
studies have shown no association between discontinuation
and age,19,20,26–29 diabetes,6,16,27,29 or smoking.27This study was aimed at identifying patient groups with
an increased likelihood to discontinue statins in a large
prospective cohort linked to prescription registers. A better
understanding of the determinants of adherence to statin
treatment is important because discontinuation is common,
and it significantly increases both the incidence of cardio-
vascular and cerebrovascular events30 and, among high-risk
patients, also all-cause mortality.31,32 Because the decision
concerning the continuation of statin-use is commonly
made during the first year of treatment,3,33 we restricted
our analysis to predictors of discontinuation during the first
year of medication.Methods
Study population and design
The data used in this study came from the Finnish Public
Sector Study,34 a prospective study of all local government
employees of 10 towns and all employees in 21 public hos-
pitals with a $6-month job contract in 1991–2005.
We initially included the 80,459 identifiable participants
who responded to a survey in 1997–1998, 2000–2002,
2004, or 2008. The questionnaires involved demographic
characteristics, lifestyle factors, and health status, and the
average response rate was 70%. We linked the survey data
to data from national health registers using unique personal
identification numbers as in our earlier studies.34,35 Among
the respondents, there were 11,949 participants who had
initiated statin medication between 1 January, 1998 and
31 December, 2010. Of them, we included all the 9285
participants who had completed a survey before the statin
therapy began and had not been dispensed statins in the pre-
vious two years. From the initiators, we identified the 1142
discontinuers (initiators who filled only one prescription
during the first year of statin treatment; Figure 1).
Follow-up data were available until 31 December 2011.
In cases of repeated surveys before initiation, we selected
the most recent response. The mean lag between the
response and statin initiation was 3.4 years (standard devi-
ation, SD 6 2.4).
Discontinuation of statin treatment
In Finland, statins are available by prescription only. The
National Health Insurance Scheme provides prescription
drug coverage for all (w5.4 million) community-dwelling
residents. All reimbursed prescriptions are registered in the
Finnish Prescription Register managed by The Social
Insurance Institution of Finland.36 Reimbursed medicines
can be supplied to a patient for three months per purchase.
For each drug, reimbursement-related factors including the
dispensing date, the World Health Organization Anatomical
Therapeutic Chemical (ATC) code,37 the quantity
dispensed, and co-payment are recorded.
80 459 participants in the Finnish Public
Sector Study responded to survey in
between 1997–2008
11 949 initiated statin therapy between
1 Jan 1998 and 31 Dec 2010 and had
not used statins in the previous 2 years
9285 respondents began statin therapy after
completing the survey and between 1 Jan 1998–
31 Dec 2010
Discontinuers (filled only one prescription during
the first year of therapy) n=1142
Continuers n=8143
68 510 respondents did not initiate
statin therapy
2664 did not complete the survey before
statin initiation
Figure 1 Flow chart of sample selection.
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filled prescriptions with the ATC code C10AA. All the
patients who initiated statin therapy were assumed to
require treatment for the rest of their lives. Discontinuation
of statin therapy was considered to take place when after
the first filled prescription, no more statin prescriptions
were filled within the subsequent 12 months. We also
recorded co-payment and the year of statin initiation due to
major changes in prescribing practices and statin costs over
time.38
Independent covariates
We assessed lifestyle factors using standard question-
naire measurements.34,35 We requested the participants’
smoking status (none, former, current) and calculated
body mass index using self-reported weight and height.
We classified body mass index into the following three
groups: normal weight (,25 kg/m2), overweight (25–
29.9 kg/m2), and obese ($30 kg/m2). We defined risky
alcohol user as a participant with either a high mean
alcohol consumption ($16 drinks per week for women
and $24 per week for men, one unit equal to 12 cl of
wine or 4 cl of spirits or 33 cl of beer) or having passed
out due to heavy alcohol consumption at least once during
the 12 months or both. Physical activity was measured by
the Metabolic Equivalent Task index; the sum score of
the Metabolic Equivalent Task hours was used to identify
active (.4 hours), moderate (2–4 hours), or low
(,2 hours) physical activity.We identified cardiovascular comorbidities (including
cardiovascular diseases and diabetes) using special reim-
bursement and hospital discharge registers (entitlements to
special reimbursement for drug treatment of chronic hy-
pertension, heart failure, coronary artery disease, or dia-
betes at statin initiation, or hospitalization for these
conditions, stroke, or arrhythmias during 36 months before
initiation).34,35 Information on cancer diagnosis within
five years before statin initiation came from the Finnish
Cancer Registry.39 Antidepressant purchases (ATC code
N06 A) during the 36 months preceding statin initiation,
captured from the Prescription Register and served as a
proxy for depression. Information on self-rated health (clas-
sified as suboptimal if average or worse vs not if good or
very good) and marital status (married or cohabiting vs sin-
gle, divorced or widowed) were obtained from the survey
responses. Data on sex and age (24–50, 51–60, 61–75 years)
came from the employers’ administrative registers. Infor-
mation on co-payment per first statin purchase (,5 euros,
5–20 euros, .20 euros) came from the Finnish Prescription
Register. Statistics Finland provided information on educa-
tion, which was classified as high (tertiary level), interme-
diate (upper secondary level), or basic (lower secondary
level or less).40
Statistical analyses
We used a logistic regression analysis to estimate the
association of discontinuation with demographic character-
istics, comorbidities, lifestyle factors, and co-payment.
990 Journal of Clinical Lipidology, Vol 10, No 4, August 2016Only the respondents with complete data on all the
predictors were included. The first model was adjusted
for the year of statin initiation. All the found significant
predictors of statin discontinuation were then simulta-
neously entered into the second model to examine their
independent effects on discontinuation. The data were
analyzed with SAS software, version 9.2 (SAS Institute,
Inc., Cary, NC).
Ethics approval
The study was approved by the ethics committee of the
Hospital District of Helsinki and Uusimaa.Results
Study population characteristics
The participants were predominately women (76%) and
highly educated (47%), and they were aged 55.7 years on
average. Almost one third of them had vascular comorbid-
ity, and one fifth was obese. Behavioral health risks were
common: 31% were physically inactive, 17% were current
smokers, and 14% were risky alcohol users (Table 1).
Discontinuation
Of the 9285 statin initiators, 88% continued medication
and 12% (n 5 1142) discontinued it. Table 1 shows the
baseline characteristics of the discontinuers and continuers,
and Table 2 gives the odds ratios (OR) and their 95% con-
fidence intervals (CI) for discontinuation adjusted for the
year of statin initiation. Of the demographic factors, only
high age was associated with a decreased odds of discontin-
uation (OR 5 0.81; 95% CI, 0.68–0.98), whereas sex,
education, and marital status were not. Of the health mea-
sures, vascular comorbidity was associated with decreased
odds of discontinuation (OR 5 0.77; 95% CI, 0.66–0.89),
whereas suboptimal perceived health, use of antidepres-
sants, and cancer history were not. Of behavior-related
risk factors, overweight (OR 5 0.83; 95% CI, 0.71–0.96)
and obesity (OR 5 0.75; 95% CI, 0.63–0.90) predicted
reduced odds of discontinuation among all the participants.
Finally, high co-payment (OR 5 1.32; 95% CI, 1.05–1.65)
predicted increased odds of discontinuation.
In the sex-stratified analyses, age and co-payment were
associated with discontinuation among the women only,
and the corresponding association of obesity and former
smoking was observed among the men only. However,
none of these sex differences were significant (test of
interaction, all P . .15). The only significant difference
between the sexes (P for interaction 5 .002) was observed
for risky alcohol use: the OR being 0.66 (95% CI, 0.47–
0.92) for the men and 1.32 (95% CI, 1.05–1.66) for the
women.Table 3 presents the independent associations of the sig-
nificant predictors found in Table 2, adjusted for each other,
and the year of statin initiation. The results from this fully
adjusted model were substantially similar to the model
adjusted for the year of statin initiation only. The associa-
tion of former smoking with discontinuation disappeared
for the men in this fully adjusted model (OR 5 0.76;
95% CI, 0.56–1.04). The difference between the sexes
observed for risky alcohol use was almost unchanged
(OR 5 0.69; 95% CI, 0.49–0.98 for the men and 1.28;
95% CI, 1.02–1.62 for the women).Discussion
Main findings
In our observational study involving a large cohort of
public sector employees, we found that older age, vascular
comorbidity, and overweight or obesity were associated
with a decreased odds of discontinuation of statin therapy.
In contrast, high-patient co-payment of the first statin
purchase was associated with an increased odds of discon-
tinuation. Among the women but not in the men, risky
alcohol use was additionally associated with an increased
risk of discontinuation.
Comparison with other studies
The rate of discontinuation was 12%, which is within the
range reported earlier.2,3,6,10,11,41,42 Some previous studies
have found that patients with cardiovascular comorbidities
are less likely to discontinue statin use than those free of
such comorbidities.3,20,43 However, a recent Danish,
population-based study of 161, 646 new statin users re-
ported discontinuers to have a slightly higher prevalence
of almost all the examined diagnoses of comorbidity,
including cardiovascular disease.11 A major limitation of
that study was its reliance on registered data only. As a
result, it was not possible to control for co-existing
behavior-related risk factors, such as obesity, smoking,
and alcohol use, which could have affected the risk of
discontinuation. In our study, we were able to control for
these health risk behaviors as they appeared before the initi-
ation of statin treatment, and we found that discontinuation
was less likely for patients with previous cardiovascular co-
morbidities than for patients free of them. These findings
suggest that patients who are the most likely to benefit
from statin therapy are the most likely to continue it.
This group of patients may be more motivated than others
due to a better understanding of the need for statin
treatment.44
It is possible that patients discontinue therapy because of
poor drug effectiveness or the development of adverse
effects. However, in the West of Scotland Coronary
Prevention Study, adverse effects accounted for only 2%
Table 1 Characteristics of the 9285 participants who began
statin therapy after completing the survey in the Finnish
Public Sector Study
Characteristic
All
(n 5 9285),
(%)
Continuer
(n 5 8143),
%
Discontinuer*
(n 5 1142),
%
Sex (n 5 9285)
Men 2211 (23.8) 23.7 24.3
Women 7074 (76.2) 76.3 75.7
Age group, y (n 5 9285)
24–50 1971 (21.2) 20.8 24.3
51–60 4811 (51.8) 52.1 49.6
61–75 2503 (27.0) 27.1 26.1
Education (n 5 9285)
High 4363 (47.0) 46.7 49.2
Intermediate 3390 (36.5) 36.9 33.9
Basic 1532 (16.5) 16.4 16.9
Marital status (n 5 9144)
Married 6976 (76.3) 76.3 76.4
Single 2168 (23.7) 23.7 23.6
Co-payment per first package (n 5 9285)
Low (,5 euros) 3700 (39.8) 39.6 41.4
Moderate
(5–20 euros)
2642 (28.5) 28.6 27.5
High
(.20 euros)
2943 (31.7) 31.8 31.1
Suboptimal self-rated health (n 5 9184)
No 5315 (57.9) 57.7 59.3
Yes 3869 (42.1) 42.3 40.7
Vascular comorbidity† (n 5 9285)
No 6458 (69.6) 68.9 74.4
Yes 2827 (30.4) 31.1 25.6
Cancer (n 5 9285)
No 9110 (98.1) 98.1 98.3
Yes 175 (1.9) 1.9 1.7
Use of antidepressants (n 5 9285)
No 7547 (81.3) 81.1 82.6
Yes 1738 (18.7) 18.9 17.4
Body mass index (n 5 9031)
,25 3286 (36.4) 35.7 41.1
25–29.9 3820 (42.3) 42.7 39.6
$30 1925 (21.3) 21.6 19.3
Smoking (n 5 8822)
None 3974 (45.0) 44.8 46.7
Former 3327 (37.8) 38.2 34.0
Current 1521 (17.2) 17.0 19.3
Risky alcohol user‡ (n 5 9067)
No 7813 (86.2) 86.3 85.1
Yes 1254 (13.8) 13.7 14.9
Physical activity (n 5 9027)
Active 3159 (35.0) 34.7 37.0
Moderate 3028 (33.5) 34.0 30.5
Low 2840 (31.5) 31.3 32.5
*Discontinuer was defined as a person, who filled only one prescrip-
tion during the first year of statin medication.
†Hypertension, heart failure, coronary artery disease, diabetes,
stroke, or arrhythmias.
‡Risky alcohol user: mean alcohol consumption $16 drinks per
week for women and $24 per week for men or passed out due to heavy
alcohol consumption at least once during the 12 months.
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30% at five years.45 In a retrospective cohort study of
107,835 patients, more than half of the study patients had
their statin discontinued, but only 3.9% of them reported
an adverse reaction as the reason for discontinuation.2
This potentially unnecessary discontinuation of statins3
may lead to preventable cardiovascular events. Indeed, a
three times higher risk of myocardial infarction has been
found among discontinuers than among patients who
continued statin treatment.46
In addition to comorbidities, higher age, overweight, and
obesity, and, for men, risky alcohol use were significantly
associated with a decreased odds of discontinuation.
Contrary to these factors, risky alcohol use among the
women was associated with an increased rate of statin
discontinuation. Previous studies support some of our
findings: younger age11,14,23,47 and alcohol misuse48 have
been shown to be associated with an increased risk for
statin nonadherence. In addition, obesity in a male popula-
tion has been shown to decrease the odds of nonadherence
(OR 5 0.87; 95% CI, 0.81–0.94).49
Consistent with previous research, in which lower out-
of-pocket expenses had a positive impact on persistence
with therapy,38 we found that a high level of patient co-
payment was an independent factor for increased statin
discontinuation. Especially in a high-risk secondary pre-
vention group with a greater total of medications, overall
co-payment can be high and thus unnecessary statin-
related costs should be avoided.
Discontinuation is an extreme form of nonadherence
(which also includes intermittent use of medication). In a
previous register study from Finland, half of all statin users
discontinued statin for at least 180 days during 10 years of
follow-up. Of the discontinuers, 47% restarted statin within
one year, and 89% by the end of the follow-up.50 In our
study, when extending the follow-up period by another
year, we found that, of the 1142 participants who discontin-
ued statin medication during the first year of therapy, 18%
filled at least one prescription during the second year of
statin treatment (i.e., re-entered as a statin user) (data not
shown). Thus, it is likely that a substantial proportion of
statin discontinuers drop of treatment permanently or for
a long period.
Strengths and limitations of our study
This is a longitudinal study based on register data linked
to questionnaires involving demographic characteristics,
lifestyle factors, and health status. Our study has a number
of strengths. First, it has a large sample size with excellent
follow-up. Second, the generalizability of our findings is
expected to be greater than in clinical trials as our study
involves a large cohort of unselected statin initiators (both
men and women) in real-world practice. Third, the Finnish
Public Sector cohort contains detailed health status infor-
mation and lifestyle factors rarely available in prescription
claims databases. Finally, owing to the universal drug
Table 2 Association between the baseline characteristics and lifestyle factors and statin discontinuation (5 filled only one
prescription during the first year of statin medication) among the 9285 initiators
Characteristic
All n 5 9285 Male n 5 2211 Female n 5 7074
OR* (95% CI) OR* (95% CI) OR* (95% CI)
Sex
Male (ref) 1.00 na na
Female 1.01 (0.86–1.17) na na
Age group, y
24–50 (ref) 1.00 1.00 1.00
51–60 0.85 (0.72–1.01) 0.95 (0.70–1.30) 0.80 (0.66–0.97)
61–75 0.81 (0.68–0.98) 1.03 (0.72–1.50) 0.74 (0.59–0.92)
Education
High (ref) 1.00 1.00 1.00
Intermediate 0.88 (0.76–1.02) 0.85 (0.62–1.17) 0.89 (0.75–1.05)
Basic 1.03 (0.85–1.24) 1.24 (0.87–1.77) 0.96 (0.77–1.20)
Marital status
Married (ref) 1.00 1.00 1.00
Single 1.00 (0.85–1.16) 0.90 (0.63–1.30) 1.02 (0.86–1.21)
Suboptimal self-rated health
No (ref) 1.00 1.00 1.00
Yes 0.97 (0.85–1.11) 1.03 (0.79–1.35) 0.95 (0.82–1.11)
Use of antidepressants
No (ref) 1.00 1.00 1.00
Yes 0.89 (0.75–1.06) 0.96 (0.63–1.46) 0.87 (0.72–1.06)
Cancer
No (ref) 1.00 1.00 1.00
Yes 0.82 (0.49–1.39) 0.92 (0.32–2.61) 0.79 (0.43–1.45)
Vascular comorbidity†
No (ref) 1.00 1.00 1.00
Yes 0.77 (0.66–0.89) 0.66 (0.49–0.89) 0.81 (0.68–0.97)
Co-payment per first package
Low (,5 euros) (ref) 1.00 1.00 1.00
Moderate (5–20 euros) 1.03 (0.87–1.23) 0.87 (0.60–1.24) 1.12 (0.92–1.36)
High (.20 euros) 1.32 (1.05–1.65) 1.02 (0.64–1.60) 1.46 (1.12–1.90)
Body mass index
,25 (ref) 1.00 1.00 1.00
25–29.9 0.83 (0.71–0.96) 0.80 (0.59–1.07) 0.83 (0.70–0.98)
$30 0.75 (0.63–0.90) 0.55 (0.36–0.83) 0.83 (0.68–1.01)
Smoking status
None (ref) 1.00 1.00 1.00
Former 0.88 (0.76–1.02) 0.70 (0.51–0.96) 0.93 (0.79–1.10)
Current 1.09 (0.91–1.31) 0.97 (0.68–1.37) 1.14 (0.92–1.41)
Risky alcohol user‡
No (ref) 1.00 1.00 1.00
Yes 1.03 (0.85–1.25) 0.66 (0.47–0.92) 1.32 (1.05–1.66)
Physical activity
Active (ref) 1.00 1.00 1.00
Moderate 0.87 (0.74–1.02) 0.92 (0.66–1.27) 0.85 (0.71–1.02)
Low 0.98 (0.84–1.15) 0.94 (0.68–1.30) 0.99 (0.83–1.19)
CI, confidence interval; OR, odds ratio; ref, reference group; na, not applicable.
*Odds ratios adjusted for the year of statin initiation.
†Hypertension, heart failure, coronary artery disease, diabetes, stroke, or arrhythmias.
‡Risky alcohol user: mean alcohol consumption $16 drinks per week for women and $24 per week for men or passed out due to heavy alcohol
consumption at least once during the 12 months.
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statins by prescription only, the prescription register pro-
vided comprehensive and valid data on statin purchases. Allstatins (C10AA) were assessed; thus switching to another
statin was possible and would not have been wrongly
interpreted as discontinuation.
Table 3 Association between significant characteristics and lifestyle factors and statin discontinuation (5 filled only one
prescription during the first year of statin medication) among the 9285 initiators. Adjusted for the factors in the model and for the year
of statin initiation
Characteristic
All n 5 9285 Male n 5 2211 Female n 5 7074
OR (95% CI) OR (95% CI) OR (95% CI)
Age group, y
24–50 (ref) 1.00 1.00 1.00
51–60 0.86 (0.73–1.01) 0.96 (0.70–1.31) 0.82 (0.68–1.00)
61–75 0.82 (0.68–0.99) 1.02 (0.70–1.48) 0.76 (0.61–0.95)
Vascular comorbidity*
No (ref) 1.00 1.00 1.00
Yes 0.80 (0.68–0.93) 0.70 (0.52–0.95) 0.83 (0.70–0.99)
Co-payment per first package
Low (,5 euros)
(ref)
1.00 1.00 1.00
Moderate (5–20
euros)
1.04 (0.88–1.23) 0.86 (0.60–1.23) 1.12 (0.92–1.36)
High (.20 euros) 1.29 (1.0–31.62) 0.99 (0.63–1.55) 1.41 (1.09–1.83)
Body mass index
,25 (ref) 1.00 1.00 1.00
25–29.9 0.85 (0.73–0.98) 0.86 (0.64–1.16) 0.85 (0.72–1.01)
$30 0.82 (0.69–0.99) 0.65 (0.43–0.99) 0.88 (0.71–1.08)
Smoking status
None (ref) 1.00 1.00 1.00
Former 0.87 (0.75–1.01) 0.76 (0.56–1.04) 0.90 (0.76–1.06)
Current 1.08 (0.90–1.29) 1.06 (0.75–1.50) 1.05 (0.85–1.30)
Risky alcohol user†
No (ref) 1.00 1.00 1.00
Yes 1.03 (0.85–1.25) 0.69 (0.49–0.98) 1.28 (1.02–1.62)
CI, confidence interval; OR, odds ratio; ref, reference group.
*Hypertension, heart failure, coronary artery disease, diabetes, stroke, or arrhythmias.
†Risky alcohol user: mean alcohol consumption $16 drinks per week for women and $24 per week for men or passed out due to heavy alcohol con-
sumption at least once during the 12 months.
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limitations. First, we have no information on the reasons for
discontinuation of statin therapy or of drug-related adverse
effects. Second, we used prescription register information
to estimate actual pill intake. This practice meant that
primary discontinuers were not included (those who never
fill the first prescription). Moreover, as with any pharmacy
claim database study, we could only determine that a
prescription was filled, not that a patient actually took the
medicine.51 Third, as we did an all-statin analysis instead of
looking at individual statins, we do not know if there are
differences in discontinuation between individual statins.
Fourth, factors related to the health care system and physi-
cian’s performances were not available, although they can
be associated with discontinuation.43,52 Fifth, self-
reporting tends to underestimate obesity and overweight53
as well as smoking and alcohol use.54,55 Finally, our study
did not include any measurement of serum lipid levels or an
assessment of patients’ total cardiovascular risk, which may
have affected the perceived need for statin therapy and the
discontinuation of it.Conclusions and implications for practice
and future research
In clinical practice, many patients for whom statins are
prescribed discontinue the use of the drug within a year,
which is likely to reduce any benefit of medication and
increase the risk of cardiovascular events.56 Our study sug-
gests that statin discontinuation is common, but several pre-
dictors of discontinuation are readily assessable and can
provide information with which to identify those with an
increased risk of nonadherence. Further intervention studies
are needed to assess whether increased efforts to motivate
treatment adherence in risk groups would reduce discontin-
uation and cardiovascular events.
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